Cerebral Vein Thrombosis Clinical Trial
Official title:
International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04569279 -
Rivaroxaban vs. Warfarin in CVT Treatment
|
Phase 3 | |
| Completed |
NCT02585713 -
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
|
Phase 3 | |
| Active, not recruiting |
NCT03329365 -
Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
|
||
| Not yet recruiting |
NCT05211102 -
Venous Sinus Thrombosis : Clinical Picture and Outcome
|
||
| Active, not recruiting |
NCT03080883 -
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
|
Phase 3 | |
| Recruiting |
NCT05021198 -
The Norwegian Cerebral Venous Thrombosis Study
|
||
| Completed |
NCT05448248 -
Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)
|